Stryker Corporation
SYK · NYSE
SYK · NYSE
Stryker is a medical-technology company that sells products used in surgery, hospital care, orthopaedics and neurotechnology. It earns revenue by selling medical devices, implants and related equipment to healthcare providers, including hospitals. The supplied evidence does not identify its reporting segments or show how revenue is divided among them, so the relative contribution of different product areas cannot be stated here. Stryker reports FY2025 revenue of $25.1 billion and net income of $3.2 billion, compared with FY2024 revenue of $22.6 billion and net income of $3.0 billion, indicating its current scale.
Stryker rose $1.12, or 0.41%, from $274.19 to $275.31 across the stated weekly endpoints. Trading was uneven: the stock first advanced to $275.09 on September 22, then fell over the next two sessions to $269.75 on September 24, before recovering to $272.36 on September 25 and reaching $275.31 on September 28. The late-week rebound more than recovered the prior decline, leaving the shares modestly higher overall. The supplied evidence identifies no company-specific announcement or catalyst to explain the moves. It also provides no market or sector benchmark, so the week’s performance cannot be attributed to broader market conditions from the available information.
Stryker fell $10.64, or 3.07%, from $346.60 to $335.96 over the week. The decisive move came after the July 30 earnings release: despite a 9% organic-sales increase, 17.9% adjusted EPS growth, and quarterly EPS and revenue beats, the company narrowed its 2026 guidance, prompting a reported 7.8% after-hours decline and a 6.7% drop to $325.70 on July 31. Shares then recovered 4.8% to $341.20 on August 3, but gave back part of that rebound the next day as investors continued weighing guidance against the cyber-disruption recovery. Broader market moves were mixed, with bond-yield volatility and technology-led gains providing limited support.
